Front Oncol: Impact of postoperative adjuvant therapy on the prognosis of limited-stage small cell lung cancer (SCLC)

Small cell lung cancer (SCLC) is divided into limited stage and extensive stage

Small cell lung cancer (SCLC) is divided into limited stage and extensive stage

The study included patients who were histologically confirmed to have surgical resection of small cell lung cancer between November 2006 and June 2019

The study included patients who were histologically confirmed to have surgical resection of small cell lung cancer between November 2006 and June 2019

The study included 153 patients, most of whom were over 60 years old (65%), male (84%), and smoking history (76%)

The 5-year survival rates of the non-adjuvant therapy group, adjuvant chemotherapy group, and adjuvant radiotherapy group were 20.

 Comparison of OS with different adjuvant treatments in the general population

For patients with pT1 stage, there is no statistical difference between the three treatment modalities

For patients with pT1 stage, there is no statistical difference between the three treatment modalities

Comparison of OS in different adjuvant treatments in subgroups

For patients with mixed SCLC, there is no statistical difference between the three treatment modalities

In summary, studies have shown that for patients with pT2-4 stage and simple SCLC, postoperative adjuvant chemotherapy and radiotherapy can improve the prognosis

Original source:

Li D, Deng C, Zheng Q, et al (2021) Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer.
Front.
Oncol.
11:704517.
doi: 10.
3389/fonc.
2021.
704517

Li D, Deng C, Zheng Q, et al (2021) Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer.
Front.
Oncol.
11:704517.
doi: 10.
3389/fonc.
2021.
704517

 

 

 

Leave a message here